What Is a Material Transfer Agreement? A U.S. Research Guide

A material transfer agreement, or MTA, is a contract that sets the rules for sharing research materials between organizations. It can cover items such as cell lines, plasmids, antibodies, compounds, plants, or animal models. An MTA spells out how a recipient may use the material, who owns it, and what restrictions apply. Understanding these terms before shipping or accepting materials can help prevent delays and clarify responsibilities for research, publication, and intellectual property.

What Is a Material Transfer Agreement?

A material transfer agreement is a written agreement between a provider and a recipient for the transfer and use of tangible research materials. The provider may be a university, company, government agency, nonprofit, or individual researcher. The recipient is usually an organization or laboratory that will use the material for research or evaluation.

An MTA typically defines permitted use, limits on redistribution, confidentiality obligations, ownership, liability, and the handling of results. It may also address publication, inventions, safety, and the return or disposal of unused material. The exact terms vary with the material, the parties, and the purpose of the transfer.

An MTA is not usually a purchase agreement. Materials may be provided without charge, but a provider may charge for preparation, packaging, shipping, or administrative costs. Payment for materials does not automatically grant the recipient broad rights to use them or commercialize results.

MTAs are common in university research, biotechnology, pharmaceutical development, agriculture, and government-funded science. They help organizations share useful tools while documenting the conditions under which those tools may be used.

What Counts as Research Material?

Research materials are tangible items supplied for research or evaluation. Biological materials are especially common, but the term can also cover nonbiological research tools. An agreement should identify the material clearly enough that both parties understand what is being transferred.

• Biological materials: cell lines, microorganisms, plasmids, DNA, tissues, antibodies, proteins, seeds, and animal models.
• Chemical materials: compounds, reagents, and other substances prepared or supplied for research.
• Research tools: specialized devices, prototypes, or equipment provided for testing or evaluation.
• Derivatives: substances or materials made from, containing, or modified from the original material, as defined in the agreement.

Data, software, and confidential information may accompany a material transfer, but they are not necessarily governed by the MTA in the same way as physical items. Data access may require a separate data-use agreement; software may need a license; and confidential information may be covered by a nondisclosure agreement. The parties should clarify which documents apply to each component of a transfer.

Why Do Organizations Use MTAs?

Sharing materials can make research faster and more reproducible. A laboratory may not have the resources to recreate a specialized cell line or reagent, while another organization may be able to provide it. An MTA creates a record of the transfer and establishes the conditions for responsible use.

For providers, an MTA can help protect ownership, limit use to an agreed research purpose, and reduce the risk of unauthorized redistribution or commercial use. For recipients, it can clarify what activities are permitted and identify obligations that could affect experiments, publications, or future development.

MTAs also help organizations assess practical concerns before a shipment occurs. These may include biosafety, handling and storage, export controls, privacy, human-subject protections, and whether the recipient has the necessary approvals. An agreement does not replace those approvals, but it can make responsibilities easier to identify.

Common Types of Material Transfer Agreements

Incoming and outgoing MTAs

An incoming MTA applies when an organization receives material from an outside provider. An outgoing MTA applies when an organization supplies material to another party. Institutions often use different review processes for each, since the risks and responsibilities differ.

Academic and nonprofit transfers

Transfers between universities or nonprofit research organizations may use terms designed for noncommercial research. Some organizations use the Uniform Biological Material Transfer Agreement, or UBMTA, for eligible transfers of biological materials. Developed through a process coordinated by the National Institutes of Health, the UBMTA provides a standard framework and an implementing letter for individual transfers. It is not automatically appropriate for every material, purpose, or organization.

Commercial or evaluation transfers

A company may provide material to another company or an academic laboratory for testing, screening, or product development. These arrangements may have more detailed terms on confidentiality, commercial rights, inventions, and access to results. A transfer described as “evaluation only” may prohibit broader research or product development, so the permitted purpose should be read carefully.

Key Terms to Review in an MTA

Permitted use and restrictions

The purpose clause is central. It may limit use to a named project, a specific laboratory, or noncommercial research. An MTA may prohibit clinical use, human administration, commercial activity, or use in particular applications. If a project changes, the recipient should not assume that the original permission still covers the new work.

Ownership, derivatives, and inventions

The provider generally retains ownership of the original material, but the agreement may define derivatives, modifications, and progeny differently. A recipient may own certain modifications or inventions under some agreements, while other terms may grant the provider rights or require further negotiation. These provisions should be reviewed alongside institutional intellectual-property policies and any sponsored-research agreements.

Publication and confidentiality

Research agreements may allow a provider to review a manuscript before publication to identify confidential information or coordinate patent filings. Review periods and any delay rights should be clearly limited. A clause that gives one party broad control over whether or when results can be published may conflict with academic publication expectations or other research commitments.

Liability and warranties

Materials are often provided “as is,” with limited or no warranties about safety, quality, or fitness for a particular purpose. Agreements may also include indemnification or liability provisions. These terms deserve particular attention because a laboratory may have limited ability to accept obligations that expose an institution or company to uncapped or third-party risk.

How the MTA Process Works

1. Confirm the transfer details. Identify the material, provider, recipient organization, intended project, and any associated data or confidential information.
2. Start institutional review. Universities and companies typically route agreements through an authorized office, such as technology transfer, contracts, research administration, or legal affairs. A researcher usually cannot sign for the institution unless specifically authorized.
3. Complete compliance checks. Depending on the material and study, reviews may involve biosafety, animal care, human-subject protections, privacy, export controls, or environmental health and safety.
4. Negotiate terms if needed. The parties resolve provisions that do not fit the project, institutional policies, funding terms, or applicable law.
5. Sign before transfer. The appropriate authorized representatives sign the agreement before the material is shipped or received.
6. Track use and closeout. Researchers follow the agreed restrictions and document whether material must be returned, destroyed, or retained when work ends.

Processing time varies. A standard institutional form may move relatively quickly, while an agreement involving commercial rights, sensitive samples, unusual liability language, or multiple compliance reviews can take longer. Starting the request early and providing complete project details can reduce avoidable back-and-forth.

Special Considerations for Human and Sensitive Materials

Human tissue, blood, identifiable specimens, and other human-derived materials may involve more than an MTA. The transfer may need to align with consent terms, institutional review board requirements, privacy protections, and applicable federal or state rules. Whether a study requires IRB review depends on the research and the nature of the information; an MTA alone does not establish that a transfer or study is authorized.

Recipients should confirm whether specimens are coded or identifiable, what information accompanies them, and whether the consent or source agreement permits the proposed use. The parties should also determine whether a data-use agreement, confidentiality agreement, or other documentation is necessary.

For infectious agents, genetically modified organisms, toxins, or animal materials, institutional biosafety and other safety reviews may be required. A signed MTA does not substitute for shipping permits, required training, containment measures, or approvals from the relevant institutional committees or government agencies.

MTAs and U.S. Research Rules

Federal funding can affect how an organization handles research materials and intellectual property. For example, the Bayh-Dole Act concerns certain inventions arising from federally funded research; it does not make every MTA clause automatically valid or determine ownership of every transferred material. Institutions must consider the agreement alongside funding obligations, patent policies, and other contracts.

International transfers may raise additional questions, including export controls, sanctions, customs requirements, and restrictions on particular technologies or biological materials. Some biological resources may also be subject to access-and-benefit-sharing rules in their country of origin or under other applicable arrangements. The details depend on the material, destination, end use, and parties involved.

Because regulatory and institutional requirements vary, researchers should consult their organization’s contracts or technology-transfer office and relevant compliance personnel before committing to terms or arranging shipment. This is especially important when a transfer includes human samples, controlled materials, international shipments, or anticipated commercial development.

Common MTA Mistakes to Avoid

• Using material before the agreement is signed: Informal permission or an email may not satisfy institutional requirements.
• Assuming “research use” means any research: The agreement may restrict purpose, location, personnel, or later applications.
• Overlooking downstream transfers: A recipient may need provider approval before sharing material with a collaborator or core facility.
• Ignoring publication and IP terms: These provisions can affect project timelines and the ability to report results.
• Leaving derivatives undefined: Unclear definitions can create disagreements about ownership, storage, and future use.
• Treating an MTA as the only approval: Safety, privacy, ethics, shipping, and regulatory requirements may apply separately.

Where to Find Reliable MTA Guidance

Researchers can begin with their institution’s technology-transfer, research contracts, or sponsored-programs office. The NIH Office of Technology Transfer provides information on the Uniform Biological Material Transfer Agreement and related material-transfer resources. The NIH guidance can help explain the standard framework, but each organization’s policies and each transfer’s circumstances still matter.

For an MTA to work well, it should match the material and the actual research plan. Clear descriptions of the permitted use, handling, publication, intellectual property, and end-of-project obligations help both parties share research materials without creating unexpected restrictions.